Assessing The Visual Performance Of Hanita Lenses "Intensity SL" Intraocular Lens
NCT ID: NCT05504343
Last Updated: 2023-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2021-12-27
2023-01-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation for Assessing the Visual Performance of Hanita Lenses Intensity SL IOL in Comparison to Alcon Panoptix IOL
NCT06084169
Post Marketing Clinical Evaluation Assessing the Visual Performance of Hanita Lenses "Intensity SL" Intraocular Lens
NCT06075459
Data Collection After Intensity IOL Implantations
NCT06220331
Clinical Evaluation Study for Assessing the Visual Performance of Hanita Lenses Trifocal IOL
NCT04843748
Visual Performance With a Hydrophobic Aspheric Monofocal IOL
NCT03819582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intensity SL intraocular lenses (IOLs) represent the latest in premium lens technology. Intensity SL lenses provide clear vision at all distances - from near to far - thus offering the best chance of true spectacle independence.
Despite the promising results obtained with the latest generation of MIOLs, many surgeons remain reluctant to implant these lenses. Visual symptoms such as glare and haloes, reduced contrast sensitivity and night vision problems are all known complications of multifocal implants and have served to hamper wider acceptance of these IOLs4.
Hanita Lenses new Intensity SL IOL has been designed to have very high efficiency of light leading to a high MTF, wide focal ranges of far, intermediate and near vision and minimal loss of light energy. The main purpose of this study is to evaluate visual acuity and contrast sensitivity patients receiving the new Intensity SL IOL.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm
This study is a prospective, single arm single center, open label study.
"Intensity SL" Intraocular Lens
Cataract surgery and intraocular lens implantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
"Intensity SL" Intraocular Lens
Cataract surgery and intraocular lens implantation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation;
* Calculated IOL power is within range 15-30 Diopter (approximate range of axial lengths: 21-25.5mm)
* Normal corneas with corneal astigmatism below following value:
1. 1 D if with-the-rule (steep axis is vertical, between 60-120⁰)
2. 0.4 D if against-the-rule (steep axis is horizontal, 0-30⁰ or 150-180⁰)
3. 0.7 D if oblique (not one of the cases above)
* Post-operative best corrected visual acuity expected to be 0.3 logMAR or better.
* Patient motivated for Intensity SL IOL after screening by surgeon.
* Fundus visualization is possible.
* Absence of retinal or optic nerve diseases
* Signed informed consent
Exclusion Criteria
* Previous ocular/corneal surgery that may affect refraction accuracy or visual acuity.
* Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome)
* History or evidence of any ocular disease that may affect visual acuity (i.e. uncontrolled glaucoma, ocular injury, corneal pathologies, retinal pathologies in general and macular pathologies in particular, diabetic retinopathy, uveitis, aniridia or iris atrophy, vitreous pathologies (patients with vitreous separation or floaters can be included).
* Rubella cataract.
* Amblyopia
* Significantly dry eye
* Any other ocular condition that may predispose a subject to future complications or contraindicate implantation of the Intensity SL lens.
* Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions)
* Patients with pupil diameter greater than 4mm in photopic conditions.
* Pregnant, lactating, or planning to become pregnant during the course of the trial.
* Allergy or intolerance to required study medications (including antibiotic).
* Subjects participating in a concurrent clinical trial or if they have participated in an ophthalmology clinical trial within the last 30 days.
* Traumatic cataract.
45 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanita Lenses
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Suvodip Shaw
Role: STUDY_DIRECTOR
Dr. Agarwal's Eye Hospital Limited
Dr Ashvin Agarwal
Role: PRINCIPAL_INVESTIGATOR
Dr. Agarwal's Eye Hospital Limited
Priyanka S.
Role: STUDY_CHAIR
Dr. Agarwal's Eye Hospital Limited
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Agrawal
Chennai, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HTF-PM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.